Srinivasan Sridhar, Takeshita Kenichi, Holkova Beata, Czuczman Myron S, Miller Kena, Bernstein Zale P, Driscoll Deborah, Chanan-Khan Asher
Department of Medicine, State University of Buffalo, New York.
HIV Clin Trials. 2004 May-Jun;5(3):140-5. doi: 10.1310/BDHX-D9BC-YWVU-9NBR.
The gastrointestinal (GI) tract is the most common site of extranodal disease in patients with systemic non-Hodgkin's lymphoma (NHL). Patients with systemic NHL and GI involvement associated with AIDS (GI-ARL) have a significantly worse prognosis than those without AIDS. We studied whether the introduction of HAART is associated with improved survival in patients with GI-ARL.
36 patients with GI-ARL were identified from the tumor registries of a large municipal hospital in New York City and a tertiary care facility in western New York State. Of these, 28 patients did not receive HAART and 8 were treated with HAART. The primary endpoint was survival, which was defined as time from date of diagnosis of NHL until death from any cause.
Patients were analyzed based on whether or not they were treated with HAART. Kaplan-Meier analysis showed significantly better survival in patients with GI-ARL who were concurrently treated with HAART (p =.014). Median survival was 5 months for the no-HAART group and 30 months for the HAART group.
In patients with GI-ARL who were treated with chemotherapy, concurrent therapy with HAART therapy was associated with improved survival.
Zotero 插件